The team’s goal is to understand if artificial intelligence (AI) can improve how survival and treatment responses are predicted in ovarian cancer.
Using the $1 million global research award, plus an additional $1 million in computing support from Microsoft’s AI for Good Lab, the team will analyse one of the largest and most comprehensive international collections of ovarian cancer data ever assembled.
The global team will integrate tumour samples, clinical records, immune response, genetic information, and lifestyle factors from thousands of patients across international research institutions.
Using fine-tuned AI models, the researchers will then analyse the data collectively to identify patterns in survival and treatment response that current tools cannot detect. By improving how patients are matched to treatments and clinical trials, the project aims to reduce unnecessary side effects, support more personalised care, and ultimately help improve survival outcomes for women with ovarian cancer.
“Ovarian cancer is an incredibly complex disease,” says Professor James Brenton, the UK lead researcher on the project and Co-Lead of our Women+s Cancers Programme. “Ongoing DNA changes in the cancer mean it can become resistant to chemotherapy, and its unique pattern of spread and ability to prevent normal immune responses, can leave our immune system unable to fight the cancer. These barriers make it very difficult to treat effectively. Our aim is to use advanced machine learning (AI) to make sense of this multi-scale complexity to develop new clinical tools that are urgently needed to more accurately predict survival and guide clinical decision-making.”
